Mr Q, 42-year-old man post-renal transplant on Mycophenolate 720 mg twice daily, needs contraception advice. Which is most appropriate?

Mr Q, 42-year-old man post-renal transplant on Mycophenolate 720 mg twice daily, needs contraception advice. Which is most appropriate?

• A. Condoms only suffice
• B. Effective contraception during treatment and for 90 days after discontinuation
• C. No contraception needed
• D. Contraception not required after stopping

Answer: (B)

Teratogenic risk is the central issue here. Mycophenolate mofetil can cause serious birth defects if a pregnancy occurs while a patient is on therapy, so contraception is essential during treatment. In male patients, there’s also concern about paternal exposure, because sperm produced during the time on the drug could potentially transmit risk to a pregnancy. To cover a full cycle of spermatogenesis and minimize any risk from sperm produced while on therapy, contraception is advised for a partner during treatment and for about 90 days after stopping the drug. That’s why the option recommending effective contraception during treatment and for 90 days after discontinuation is the best choice. It reflects the need to prevent pregnancy while MMF is active and to allow enough time for sperm to turnover after stopping the drug. Contraception during therapy and after stopping isn’t optional here because ignoring either period could expose a pregnancy to teratogenic risk, which rules out no contraception and contraception not required after stopping. Relying on a single method (like condoms only) is also less robust than ensuring effective contraception throughout the treatment and the post-treatment window.

Teratogenic risk is the central issue here. Mycophenolate mofetil can cause serious birth defects if a pregnancy occurs while a patient is on therapy, so contraception is essential during treatment. In male patients, there’s also concern about paternal exposure, because sperm produced during the time on the drug could potentially transmit risk to a pregnancy. To cover a full cycle of spermatogenesis and minimize any risk from sperm produced while on therapy, contraception is advised for a partner during treatment and for about 90 days after stopping the drug.

That’s why the option recommending effective contraception during treatment and for 90 days after discontinuation is the best choice. It reflects the need to prevent pregnancy while MMF is active and to allow enough time for sperm to turnover after stopping the drug.

Contraception during therapy and after stopping isn’t optional here because ignoring either period could expose a pregnancy to teratogenic risk, which rules out no contraception and contraception not required after stopping. Relying on a single method (like condoms only) is also less robust than ensuring effective contraception throughout the treatment and the post-treatment window.